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Two patients abruptly developed congestive heart failure and elevations in serum transami-
nase levels when given disopyramide phosphate; enzyme abnormalities and hemodynamic
status corrected upon withdrawal of the drug. Both patients had underlying ischemic cardiomy-
opathy. Myocardial infarction, pulmonary embolism, and viral hepatitis were ruled out in both
patients. One patient had a liver biopsy documenting central hepatic necrosis with congestion,
consistent with hepatic ischemia and not toxic hepatitis. In the other patient, cardiac decompen-
sation and hepatocellular enzyme elevation were reproduced on rechallenge with the drug.
Disopyramide should be used with caution in patients with heart failure.
Disopyramide phosphate (DP) is an antiarrhythmic drug that resembles quinidine
in its electrophysiologic properties. Because it spares the patient many of the
gastrointestinal side effects of quinidine, DP is becoming widely used [1]. However,
DP has been shown to have a myocardial depressant effect which may be especially
pronounced in patients with underlying heart failure [1-4]. Two cases are reported
here in which transient but marked elevations in hepatocellular enzymes had a clear
temporal relation to cardiac decompensation induced by DP in patients with
ischemic cardiomyopathy.
CASE REPORTS
Case I
A 62-year-old man was admitted to Yale-New Haven Hospital with congestive
heart failure and ventricular ectopy. His past history included hypertension, coronary
artery disease with inferior wall myocardial infarction, chronic obstructive lung
disease, and transient ischemic attacks successfully treated by right carotid endarter-
ectomy. He was taking furosemide, prazosin, and digoxin for heart failure, and was
also taking allopurinol. Quinidine was started for ventricular ectopy but had to be
stopped when abdominal cramps, nausea, and vomiting developed; these symptoms
then resolved. He had no prior history ofliver disease, took alcohol rarely, and had
no exposure to known hepatotoxins.
On admission he was afebrile, in mild respiratory discomfort with 24 respirations
per minute, a pulse of 100, and a blood pressure of 160/80. He had jugular venous
distention, bilateral carotid bruits, bibasilar pulmonic rales, and a left ventricular lift.
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All rights of reproduction in any form reserved.A II/VI early systolic murmur was heard at the apex, with a normally split S2 and an
S4 gallop. The liver was estimated to be 13 cm in span by percussion; he had trace
peripheral edema. Chest X-ray showed cardiomegaly with redistribution of pulmon-
ary flow to the upper lobes. His electrocardiogram showed sinus rhythm with a PR
interval of 0.16 sec, a QRS interval of 0.11 sec with a left ventricular conduction
delay, inferior Q waves, and lateral ST segment depressions. Serum potassium,
SGOT, LDH, bilirubin, alkaline phosphatase, creatine kinase, and prothrombintime
were normal. The only serum abnormality was a BUN of 32.
On the morning following admission (day 2) the patient was given DP 250 mg
orally followed by 150 mg orally four times a day. That evening he complained of
anxiety and dyspnea. ECG was unchanged from that of admission. By the next
morning, however, his PR interval had lengthened to 0.20 sec, his BUN was 47, and
his SGOT rose to 98 units (normal less than 35). The SGOT peaked at 4780 units on
day 4. On day 5 the right upper abdomen was tender. Digoxin was held when his
serum level was found to be 3.2 ng/ml (therapeutic 0.5 to 2.0). The PR interval on
that day was 0.22 sec and his QRS had widened to 0.13 sec with a left bundle branch
block pattern. DP was discontinued after ten doses, and his ectopy was treated with
lidocaine. A ventilation/perfusion lung scan was interpreted as showing a low
probability of pulmonary embolism. Serial creatine kinase measurements revealed 0
percent MB (cardiac) fraction. The ECG changes resolved by day 7.
The SGOT fell after discontinuation of DP (see Fig. 1). LDH peaked at 10,000
units (normal below 600) on day 4 and fell to normal by day 9. Bilirubin was mildly
elevated with total 2.1 mg percent and direct 0.7 mg percent. Alkaline phosphatase
remained normal, and titers for hepatitis B surface antigen, cytomegalovirus,
toxoplasma, and antinuclear antibody were all negative. Nucleated red blood cells
were seen for several days on the peripheral blood smear. By day 7 the liver was non-
tender. On day 8 a percutaneous liver biopsy was performed. The specimen showed
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central hepatic necrosis with congestion. This picture was felt to be consistent with
hepatic ischemia but not with drug toxicity.
On day 12 DP was restarted with one oral dose of 300 mg followed six hours later
by 150 mg orally. That evening the patient again complained ofanxietyand dyspnea.
His arterial oxygen tension had not fallen. DP was discontinued, and dyspnea
resolved. He was subsequently treated with procainamide, which he has tolerated
well. Liver function tests remain normal.
Case 2
This 61-year-old man was admitted to the West Haven Veterans Administration
Hospital with hypotension and chest pain following an oral dose of DP. His past
history included colon carcinoma resected nine years earlier, with no evidence of
recurrence; low-grade transitional cell bladder cancer for six years; coronary artery
disease with two myocardial infarctions and a successful two-vessel coronary artery
bypass graft for unstable angina; and a cerebral embolus following conversion from
atrial fibrillation. After this episode he was in sinus rhythm with digoxin and
quinidine. Congestive heart failure was treated with digoxin, furosemide, triamter-
ene, and sorbitrate. Three months before admission the patient had been evaluated
for hepatic fullness. Liver function tests were normal except for a bilirubin of 2 mg
percent and a prothrombin time of 14 sec with a control of 12 sec. Radiocolloid scan
of the liver and abdominal ultrasound examination both revealed hepatomegaly
without filling defects. Because the liver size and discomfort decreased with diuresis
this was felt to represent chronic passive hepatic congestion.
The patient had been seen earlier on the day of admission complaining of nausea
and a rash. His blood pressure was 150/100, scant bibasilar rales were heard, a
holosystolic murmur and an S3 were present, the liver span was 8 cm by percussion,
and 1+ peripheral edema was present. These findings were consistent with previous
examinations. A maculopapular rash was now evident on the trunk and arms.
Electrocardiogram showed a sinus rhythm with a PR interval of 0.20 sec, QRS
interval 0.10 sec with a left ventricular conduction delay unchanged from previous
tracings. Chest radiograph showed his heart failure to be somewhat better than on
previous films. Serum digoxin concentration was within therapeutic range. A
quinidine level, drawn five hours after the previous dose, was 4.6 ng/ml (therapeutic
2-6). Since the nausea and rash were presumed to be caused by quinidine, he was
given DP 300 mg orally with a prescription for further doses, and was instructed to
stop his quinidine.
He returned four hours later complaining ofsubsternal chest pain and dyspnea. He
was diaphoretic, with a pulse of 70, blood pressure 100/70, respiratory rate 26 per
minute, with rales halfway up both lung bases. The S3 and systolic murmur were still
audible. His liver was non-tender and normal in span, he had 1+ edema, and his rash
was improved. Chest X-ray showed pulmonary edema. The ECG now revealed no p
waves and a new complete left bundle branch block, with QRS interval 0.20 sec. The
rhythm was regular at a rate of 70 per minute. BUN has risen from 14 to 28 in four
hours. Serum potassium was normal.
A transvenous pacemaker was inserted. During passage through the right atrium
no atrial activity could be recorded. A Swan-Ganz catheter was placed in the
pulmonary artery. Pulmonary artery pressure was 70/30 with a pulmonary capillary
wedge pressure of 32. The patient was treated with diuretics, and dopamine and
nitroprusside infusions. Within 24 hours his cardiac rhythm and QRS complexes had
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systemic blood pressure was normal. An echocardiogram showed severe LV and LA
dilatation. Ventilation/perfusion lung scan was consistent with a low probability for
pulmonary embolism. Frequent creatine kinase determinations were all normal.
SGOT peaked that evening at 620 units and subsequently fell(see Fig. 2). SGPT rose
exactly in parallel, and LDH rose to 2½/2 times normal on the evening of admission.
Alkaline phosphatase remained normal.
The patient did well for several days. Ectopy was treated with lidocaine. Rechal-
lenge with a single dose of quinidine reproduced the rash. Because of multifocal
ventricular ectopy and runs of ventricular tachycardia, the patient was restarted on
DP 150 mg orally every six hours, on day 6. On day 7 he reported nausea and
dyspnea, and on day 8 he was returned to the coronary care unit with angina. On the
morning of day 9, two hours after his DP dose, he became hypotensive, with chest
pain, left bundle branch block, and atrial standstill. DP was discontinued. A
pacemaker and Swan-Ganz catheter were again inserted; elevated filling pressures
were again found, and responded to diuresis. Within twelve hours the hemodynamic
and ECG changes had all resolved. Myocardial infarction was ruled out. Again,
LDH, SGOT, and SGPT rose strikingly, in concert, until day 12, and then fell. The
highest measured SGOT was 1495 units on day 12, and LDH on that day peaked at
seven times normal. Alkaline phosphatase rose to less than twice normal. Hepatitis
antigen was negative. Liver enzymes returned to normal.
The patient is now doing well with his ventricular ectopy controlled on procain-
amide.
DISCUSSION
Left ventricular failure can result in ischemic hepatic injury with symptoms and
chemical findings resembling acute hepatitis [5]. This can occur with or without the
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clinical syndrome ofchronic passive hepatic congestion due to right heart failure[5,6]
and need not follow an identifiable hypotensive episode [5].
Disopyramide has been shown in dogs to have a more pronounced negative
inotropic effect than quinidine, and to do so in lower doses. The effect with DP is
dose-related [7]. In man, DP given intravenously significantly reduces cardiac output
and stroke volume in patients whose filling pressures were already elevated [2]. The
reduction in cardiac output is in the range of 18 percent withintravenous administra-
tion of 2 mg/kgin humans [3]. Clinical congestive heart failure occurs in a significant
proportion of patients treated with DP [4]. One case of cardiogenic shock has been
reported previously in a patient on chronic oral therapy with DP [8].
Patient 2, with chronic passive congestion, elevated his hepatocellular enzymes in
the setting of cardiogenic shock which was not the result of acute myocardial
infarction and which resolved on withholding DP. The duplication of this scenario
on rechallenge with DP strongly implicates this drug as the cause. Patient 1 did not
become hypotensive, though his rise in BUN was felt to represent hypoperfusion. His
liver biopsy confirmed ischemic liver damage. Furthermore, the finding of nucleated
RBCs in his peripheral blood is consistent with tissue hypoxia which can be seen in
patients with the shock liver syndrome [9,10].
Both patients developed conduction disturbances. Patient I had first degree A-V
block, which could have been related eitherto his elevated digoxin level or to DP, but
this widened QRS interval could not be explained by digitalis excess. In the second
patient, atrial standstill and widening of the QRS may have been due to DP or to
hypotension with resultant myocardial ischemia. Conduction disturbances can reflect
DP toxicity, especially in patients with underlying conduction disease [1].
In a recent study, 16 of 100 patients placed on DP developed congestive heart
failure; 12 of these patients had a history of cardiac decompensation. Remarkably,
among the 38 patients receiving chronic DP therapy, 12 of the 13 patients with any
history of congestive failure suffered cardiac decompensation on DP [4]. Hepatic
injury has not been recorded with the use of DP, other than isolated reports of
intrahepatic cholestasis [I 1,12].
Both patients reported here, despite underlying cardiomyopathy, were able to
tolerate quinidine, lidocaine, and procainamide without adverse hemodynamic
consequences, but could not tolerate DP. In such patients, "loading doses" of DP
should probably be avoided, and lower initial doses should be chosen. Maintenance
requirements can be guided by serum levels. The presence of passive hepatic
congestion may constitute a relative contraindication to the use of DP, and the drug
should be used with caution in any patient with a history of congestive heart failure.
REFERENCES
1. Koch-Weser J: Disopyramide. N Engl J Med 300:957-962, 1979
2. Hulting J, Rosenhamer G: Hemodynamic and electrocardiographic effects ofdisopyramide in patients
with ventricular arrhythmia. Acta Med Scand 199:41-51, 1976
3. Danilo P, Rosen MR: Cardiac effects of disopyramide. Am Heart J 92:532-536, 1976
4. Podrid PJ, Schoeneberger A, Lown B: Congestive heart failure caused by oral disopyramide. N Engl J
Med 302:614-617, 1980
5. Cohen JA, Kaplan MM: Left-sided heart failure presenting as hepatitis. Gastroenterol 74:583-587,
1978
6. Bloth B, de Faire U, Edhag 0: Extreme elevation of transaminase levels in acute heart disease. Acta
Med Scand 200:281-288, 1976
7. Mathur PP: Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate. Am
Heart J 84:764-770, 1972366 SCHEINMAN ET AL.
8. Story JR, Abdulla AM, Frank MJ: Cardiogenic shock and disopyramide phosphate. JAMA
242:654-655, 1979
9. Frumin AM, Mendell TH, Mintz SS, et al: Nucleated red blood cells in congestive heart failure. Circ
20:367-370, 1959
10. Tavassoli M: Erythroblastemia. West J Med 122:194-198, 1975
11. Meinertz T, Langer KH, Kasper W, et al: Disopyramide-induced intrahepatic cholestasis. Lancet
2:828-829, 1977 (letter)
12. Riccioni N, Bozzi L, Susum N, et al: Disopyramide-induced intrahepatic cholestasis. Lancet
2:1362-1363, 1977 (letter)